US67080N1019
© BusinessWire
26.11.2025
NUVB
LISTED
NYSE
Nuvation Bio to Participate in Upcoming Investor Conferences
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
NUVB
LISTED
NYSE
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
“We are thrilled that 204 new patients have received IBTROZI during our first full quarter as a commerc...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
NUVB
LISTED
NYSE
Nuvation Bio to Participate in Upcoming Investor Conferences
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor confere...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
23.10.2025
NUVB
LISTED
NYSE
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 (NCT05303519), a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients w...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
20.10.2025
NUVB
LISTED
NYSE
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025.
Investors and the general p...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
NUVB
LISTED
NYSE
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 study evaluating the efficacy and safety of IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adju...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
NUVB
LISTED
NYSE
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent n...
Themefolio
Profiler
Peergroup
© BusinessWire
07.09.2025
NUVB
LISTED
NYSE
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (R...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
NUVB
LISTED
NYSE
Nuvation Bio to Participate in Upcoming Investor Conferences
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor confere...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
NUVB
LISTED
NYSE
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025.
Investors and the general...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
NUVB
LISTED
NYSE
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung c...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
NUVB
LISTED
NYSE
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lun...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.05.2025
NUVB
LISTED
NYSE
Nuvation Bio to Participate in Upcoming Investor Conferences
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at three upcoming investor...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
NUVB
LISTED
NYSE
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
“Nuvation Bio continued to execute with focus in the first quarter as we prepare for the potential U.S. approval and la...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
NUVB
LISTED
NYSE
Nuvation Bio to Present at The Citizens Life Sciences Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at The Citizens Life Sciences Conference on Thursday, May 8, 2025, at 10:00 a.m. ET in New York, NY.
A live webc...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
NUVB
LISTED
NYSE
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial resul...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
NUVB
LISTED
NYSE
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
NUVB
LISTED
NYSE
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
NUVB
LISTED
NYSE
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentatio...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
NUVB
LISTED
NYSE
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
“Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHe...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
NUVB
LISTED
NYSE
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard). The transaction comprises a royalty interest financing of $150 million and a senior term loan of up to $100 million. These...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
NUVB
LISTED
NYSE
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA.
A...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
NUVB
LISTED
NYSE
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
NUVB
LISTED
NYSE
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT in San Franc...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
NUVB
LISTED
NYSE
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that China’s National Medical Products Administration (NMPA) has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (N...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
NUVB
LISTED
NYSE
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company’s NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FD...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
NUVB
LISTED
NYSE
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today ann...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
NUVB
LISTED
NYSE
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today ann...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
NUVB
LISTED
NYSE
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gabl...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
NUVB
LISTED
NYSE
Nuvation Bio to Present at the Jefferies London Healthcare Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Jefferies London Healthcare Conference in London, U.K., on Tuesday, November 19, 2...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
NUVB
LISTED
NYSE
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, reflected...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2024
NUVB
LISTED
NYSE
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO).
Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within h...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
NUVB
LISTED
NYSE
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
NUVB
LISTED
NYSE
Nuvation Bio to Present at the Cantor Global Healthcare Conference
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Cantor Global Healthcare Conference in New York, NY on Thursday, September 19, 202...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
